Stay updated on APL-2 in Neovascular AMD Clinical Trial

Sign up to get notified when there's something new on the APL-2 in Neovascular AMD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the APL-2 in Neovascular AMD Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the safety assessment of Pegcetacoplan in patients with Neovascular AMD in a Phase Ib/II study.
    Difference
    0.1%
    Check dated 2024-06-06T14:48:43.000Z thumbnail image
  4. Check
    5 days ago
    No Change Detected
  5. Check
    6 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for study participants, specifying age, visual acuity, and prior treatments required for inclusion, as well as various exclusion criteria. Previously, no information was provided under the Participation Criteria section.
    Difference
    43%
    Check dated 2024-05-22T21:29:12.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:39:55.000Z thumbnail image

Stay in the know with updates to APL-2 in Neovascular AMD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the APL-2 in Neovascular AMD Clinical Trial page.